Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTOR Citius Oncology	$1.75 +7.4%	$2.46	$0.55 ▼ $6.19	$137.15M	3	468,200 shs	281,705 shs
ESLA Estrella Immunopharma	$0.97 +10.2%	$0.89	$0.63 ▼ $1.78	$32.62M	0.34	11,009 shs	4,629 shs
FATE Fate Therapeutics	$1.15 +3.6%	$1.13	$0.66 ▼ $4.20	$128.02M	2.24	1.48 million shs	1.84 million shs
HURA TuHURA Biosciences	$3.25 +11.7%	$2.62	$1.80 ▼ $8.40	$145.64M	0.04	766,825 shs	612,913 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTOR Citius Oncology	+7.36%	+3.55%	-3.85%	+92.31%	-9.33%
ESLA Estrella Immunopharma	+10.22%	+8.01%	+7.77%	-6.74%	-31.21%
FATE Fate Therapeutics	+3.60%	+5.50%	-10.16%	-0.86%	-70.59%
HURA TuHURA Biosciences	+11.68%	+6.21%	+10.17%	+14.84%	+324,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTOR Citius Oncology	1.3567 of 5 stars	3.0	0.0	0.0	1.8	1.7	0.0
ESLA Estrella Immunopharma	2.2714 of 5 stars	3.5	5.0	0.0	0.0	1.7	0.0
FATE Fate Therapeutics	4.1388 of 5 stars	3.1	2.0	4.7	2.6	2.5	0.6
HURA TuHURA Biosciences	1.3236 of 5 stars	3.7	0.0	0.0	1.2	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTOR Citius Oncology	2.00	Hold	$3.00	71.43% Upside
ESLA Estrella Immunopharma	3.00	Buy	$16.00	1,549.65% Upside
FATE Fate Therapeutics	2.14	Hold	$3.30	186.96% Upside
HURA TuHURA Biosciences	3.40	Buy	$12.67	289.74% Upside

Current Analyst Ratings Breakdown

Latest ESLA, CTOR, FATE, and HURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$4.00 ➝ $2.50
8/12/2025	ESLA Estrella Immunopharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/23/2025	HURA TuHURA Biosciences	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/29/2025	ESLA Estrella Immunopharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/23/2025	CTOR Citius Oncology	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/23/2025	CTOR Citius Oncology	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.41 per share	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	($0.16) per share	N/A
FATE Fate Therapeutics	$13.63M	9.73	N/A	N/A	$2.27 per share	0.51
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.38 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTOR Citius Oncology	N/A	N/A	0.00	∞	N/A	N/A	-51.93%	-22.17%	N/A
ESLA Estrella Immunopharma	N/A	-$0.26	N/A	∞	N/A	N/A	-1,132.38%	-358.54%	9/26/2025 (Estimated)
FATE Fate Therapeutics	-$186.26M	-$1.45	N/A	N/A	N/A	-2,025.05%	-50.95%	-36.76%	11/11/2025 (Estimated)
HURA TuHURA Biosciences	-$21.68M	N/A	0.00	∞	N/A	N/A	-248.79%	-150.83%	10/6/2025 (Estimated)

Latest ESLA, CTOR, FATE, and HURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	HURA TuHURA Biosciences	-$0.14	-$0.21	-$0.07	-$0.21	N/A	N/A
8/12/2025	Q2 2025	FATE Fate Therapeutics	-$0.35	-$0.29	+$0.06	-$0.29	$1.16 million	$1.91 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTOR Citius Oncology	0.12	0.35	0.02
ESLA Estrella Immunopharma	N/A	0.16	0.16
FATE Fate Therapeutics	N/A	8.04	8.04
HURA TuHURA Biosciences	N/A	0.83	3.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTOR Citius Oncology	70.52%
ESLA Estrella Immunopharma	0.35%
FATE Fate Therapeutics	97.54%
HURA TuHURA Biosciences	0.62%

Insider Ownership

Company	Insider Ownership
CTOR Citius Oncology	4.57%
ESLA Estrella Immunopharma	55.10%
FATE Fate Therapeutics	5.51%
HURA TuHURA Biosciences	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTOR Citius Oncology	N/A	78.37 million	74.79 million	N/A
ESLA Estrella Immunopharma	N/A	37.07 million	16.64 million	Not Optionable
FATE Fate Therapeutics	550	115.33 million	108.98 million	Optionable
HURA TuHURA Biosciences	N/A	50.05 million	49.95 million	N/A

ESLA, CTOR, FATE, and HURA Headlines

Recent News About These Companies

TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference

August 20 at 8:00 AM | prnewswire.com

TuHURA Biosciences (NASDAQ:HURA) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS

August 18, 2025 | marketbeat.com

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

August 14, 2025 | prnewswire.com

TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Rating of "Buy" from Brokerages

August 14, 2025 | marketbeat.com

TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Recommendation of "Buy" from Brokerages

August 13, 2025 | americanbankingnews.com

TuHURA Biosciences files to sell 4.76M shares of common stock for holders

August 12, 2025 | msn.com

TuHURA Biosciences, Inc.'s (NASDAQ:HURA) last week's 11% decline must have disappointed retail investors who have a significant stake

August 12, 2025 | finance.yahoo.com

TuHURA Biosciences (NASDAQ:HURA) Stock Acquired Rep. Laurel M. Lee

August 12, 2025 | marketbeat.com

TuHURA Biosciences, Inc. Common Stock (HURA) Insider Activity

July 14, 2025 | nasdaq.com

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - Seeking Alpha

July 3, 2025 | seekingalpha.com

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - Morningstar

July 3, 2025 | morningstar.comM

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

July 1, 2025 | finance.yahoo.com

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000Â® and Russell 2000Â® Indexes

July 1, 2025 | prnewswire.com

TuHURA Biosciences, Inc.: TuHURA Biosciences Completes Acquisition of Kineta

June 30, 2025 | finanznachrichten.de

TuHURA Biosciences Completes Acquisition of Kineta

June 30, 2025 | prnewswire.com

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals - Morningstar

June 25, 2025 | morningstar.comM

TuHURA initiates phase 3 trial for cancer immunotherapy drug

June 25, 2025 | uk.investing.com

TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or ...

June 25, 2025 | morningstar.comM

TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma

June 24, 2025 | prnewswire.com

Tuhura Biosciences Surges After-Hours As Investors Bet On Kineta Merger, Cancer Drug Pipeline

June 23, 2025 | msn.com

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

June 23, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ESLA, CTOR, FATE, and HURA Company Descriptions

Citius Oncology NASDAQ:CTOR

$1.75 +0.12 (+7.36%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.72 -0.03 (-2.00%)

As of 08/22/2025 07:54 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Estrella Immunopharma NASDAQ:ESLA

$0.97 +0.09 (+10.22%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$0.90 -0.07 (-7.62%)

As of 08/22/2025 04:10 PM Eastern

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Fate Therapeutics NASDAQ:FATE

$1.15 +0.04 (+3.60%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.16 +0.01 (+0.87%)

As of 08/22/2025 06:56 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

TuHURA Biosciences NASDAQ:HURA

$3.25 +0.34 (+11.68%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.22 -0.03 (-0.89%)

As of 08/22/2025 07:56 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time